Jane Street Group LLC Raises Stock Position in Agenus Inc. (NASDAQ:AGEN)

Jane Street Group LLC lifted its stake in shares of Agenus Inc. (NASDAQ:AGEN) by 97.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 105,705 shares of the biotechnology company’s stock after buying an additional 52,215 shares during the quarter. Jane Street Group LLC owned about 0.45% of Agenus worth $290,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the stock. Apollon Wealth Management LLC purchased a new stake in Agenus in the 4th quarter valued at $55,000. Virtu Financial LLC purchased a new stake in Agenus in the 4th quarter valued at $51,000. Bank of Montreal Can purchased a new stake in Agenus in the 4th quarter valued at $69,000. Barclays PLC lifted its stake in shares of Agenus by 17.7% in the 4th quarter. Barclays PLC now owns 32,737 shares of the biotechnology company’s stock worth $90,000 after acquiring an additional 4,924 shares during the period. Finally, Gilead Sciences Inc. acquired a new stake in shares of Agenus in the 4th quarter worth $635,000. Hedge funds and other institutional investors own 61.46% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Robert W. Baird raised their target price on shares of Agenus from $3.00 to $4.00 and gave the stock a “neutral” rating in a research note on Tuesday, May 13th. B. Riley restated a “buy” rating on shares of Agenus in a research note on Monday, April 21st. HC Wainwright restated a “neutral” rating on shares of Agenus in a research note on Tuesday, May 13th. Finally, Wall Street Zen upgraded Agenus from a “strong sell” rating to a “hold” rating in a research note on Thursday, May 22nd. Six equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $9.00.

Agenus Stock Up 21.1%

NASDAQ:AGEN opened at $5.00 on Wednesday. Agenus Inc. has a fifty-two week low of $1.38 and a fifty-two week high of $19.69. The stock has a market cap of $137.09 million, a PE ratio of -0.44 and a beta of 1.48. The firm’s fifty day simple moving average is $2.73 and its 200-day simple moving average is $2.90.

Agenus (NASDAQ:AGEN) last issued its quarterly earnings data on Monday, May 12th. The biotechnology company reported ($1.03) EPS for the quarter, beating analysts’ consensus estimates of ($1.61) by $0.58. The business had revenue of $24.07 million during the quarter, compared to analyst estimates of $26.38 million. Equities analysts anticipate that Agenus Inc. will post -12.55 earnings per share for the current year.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.